Abstract | OBJECTIVE: METHODS: Forty-four participants with ASD were enrolled in a 6 week, forced titration, open label examination of the selective serotonin reuptake inhibitor (SSRI) escitalopram. Doses increased at weekly intervals starting at 2.5mg daily with a maximum possible dose of 20 mg daily achieved by the end of the study. If adverse events were experienced, participants subsequently received the previously tolerated dose for the duration of study. SLC6A4 (5-HTTLPR) and HTR2A (rs7997012) genotype groups were assessed in relation to treatment outcomes and drug doses. RESULTS: Insistence on sameness and irritability symptoms significantly improved over the course of the 6 week treatment period (p<0.0001) in this open-label trial. There were no significant differences observed in the rate of symptom improvement over time across genotype groups. Similarly, dosing trajectory was not significantly associated with genotype groups. CONCLUSIONS: Previous studies have identified SLC6A4 and HTR2A associations with SSRI response in patients with depression and 5-HTTLPR (SLC6A4) associations with escitalopram response in ASD. We did not observe evidence for similar relationships in this ASD study.
|
Authors | Fedra Najjar, Thomas Owley, Matthew W Mosconi, Suma Jacob, Kwan Hur, Stephen J Guter, John A Sweeney, Robert D Gibbons, Edwin H Cook, Jeffrey R Bishop |
Journal | Journal of child and adolescent psychopharmacology
(J Child Adolesc Psychopharmacol)
Vol. 25
Issue 6
Pg. 467-74
(Aug 2015)
ISSN: 1557-8992 [Electronic] United States |
PMID | 26262902
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Receptor, Serotonin, 5-HT2A
- SLC6A4 protein, human
- Serotonin Plasma Membrane Transport Proteins
- Serotonin Uptake Inhibitors
- Citalopram
|
Topics |
- Adolescent
- Adult
- Autism Spectrum Disorder
(drug therapy, genetics)
- Child
- Child, Preschool
- Citalopram
(administration & dosage, therapeutic use)
- Dose-Response Relationship, Drug
- Female
- Genotype
- Humans
- Male
- Pharmacogenetics
- Polymorphism, Single Nucleotide
- Receptor, Serotonin, 5-HT2A
(genetics)
- Serotonin Plasma Membrane Transport Proteins
(genetics)
- Selective Serotonin Reuptake Inhibitors
(administration & dosage, therapeutic use)
- Treatment Outcome
- Young Adult
|